PRM-151 is a recombinant human serum amyloid P/pentraxin 2 protein developed by Promedior, a biotechnology company developing therapies for fibrotic diseases using plasma-derived proteins and peptides. Also referred to as PTX2, the therapy is injected intravenously in patients and is showing promise as an effective anti-fibrotic agent which can be used to target several rare orphan diseases with unmet therapeutic needs.
Promedior is currently focusing on rare systemic fibrotic diseases and their prime targets include idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal fibrovascular diseases.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?